Pfizer Inc
PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3053% above fair value
$30.67+0.15 (+0.49%)
Close on Nov 2, 2026Market cap $174.81BP/E 40.4Yield 5.61%
Pfizer Postretirement Plans by Quarter
Postretirement Plans — Net periodic benefit cost/(credit) ($M) ($M)
Pfizer Postretirement Plans: -$14M in Q2 2026, down 63.2% from a year earlier.
Latest, Q2 2026
-14
Period ended Jun 28, 2026
Change on a year earlier
-63.2%
-38 in Q2 2025
History
38 quarters
Since Q1 2017
Sources
33
Documents cited below
Where the Q2 2026 figure comes from
Source: Form 10-Q (filed 2026-08-04) ↗
Reported in Form 10-Q / 10-K Benefit Plans Footnote.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Pfizer Postretirement Plans ($M), quarterly Q1 2017–Q2 2026 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/db-cost-post
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.